Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

SIMPLE SUMMARY: The ToGA trial has demonstrated, in HER2-expressing patients, that unresectable and advanced gastric cancer, chemotherapy and trastuzumab in combination increase overall survival, even if it is still unclear why after one year the same patients are non-responsive to trastuzumab treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers (Basel)
Hauptverfasser: Laterza, Maria Maddalena, Ciaramella, Vincenza, Facchini, Bianca Arianna, Franzese, Elisena, Liguori, Carmela, De Falco, Stefano, Coppola, Paola, Pompella, Luca, Tirino, Giuseppe, Berretta, Massimiliano, Montella, Liliana, Facchini, Gaetano, Ciardiello, Fortunato, de Vita, Ferdinando
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8150287/
https://ncbi.nlm.nih.gov/pubmed/34066144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102339
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge